Research analysts at HC Wainwright started coverage on shares of Telix Pharmaceuticals (NASDAQ:TLX - Get Free Report) in a research report issued on Thursday, MarketBeat Ratings reports. The firm set a "buy" rating and a $23.00 price target on the stock. HC Wainwright's price objective points to a potential upside of 39.39% from the company's current price.
Other equities analysts have also issued reports about the stock. Wedbush reiterated an "outperform" rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a report on Thursday, June 12th. William Blair reiterated an "outperform" rating on shares of Telix Pharmaceuticals in a report on Wednesday, March 12th.
Read Our Latest Report on Telix Pharmaceuticals
Telix Pharmaceuticals Trading Up 2.6%
NASDAQ TLX opened at $16.50 on Thursday. The business's fifty day simple moving average is $16.97 and its 200-day simple moving average is $16.95. The company has a current ratio of 2.78, a quick ratio of 2.66 and a debt-to-equity ratio of 0.99. Telix Pharmaceuticals has a 52 week low of $13.61 and a 52 week high of $30.36.
Institutional Investors Weigh In On Telix Pharmaceuticals
A hedge fund recently bought a new stake in Telix Pharmaceuticals stock. Private Advisor Group LLC acquired a new position in shares of Telix Pharmaceuticals Limited (NASDAQ:TLX - Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 10,140 shares of the company's stock, valued at approximately $170,000.
About Telix Pharmaceuticals
(
Get Free Report)
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Telix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.
While Telix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
